Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.59%
As of Friday, July 31, Tyra Biosciences, Inc.’s TYRA share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Commentary & Analysis
Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.21%
As of Friday, July 10, Tyra Biosciences, Inc.’s TYRA share price has dipped by 5.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.76%
As of Wednesday, July 01, Tyra Biosciences, Inc.’s TYRA share price has dipped by 5.76%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Up 5.22%
As of Monday, June 15, Tyra Biosciences, Inc.’s TYRA share price has surged by 5.22%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 7.81%
As of Thursday, June 04, Tyra Biosciences, Inc.’s TYRA share price has dipped by 7.81%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TYRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,896.5 | $252.6 | 53% |
|
| Shares Out (Mil) | 61.7 | 52.3 | 53% |
|
| Institutional Ownership | 96.2% | 92.1% | 69% |
|
| Float (Mil) | 30.9 | 40.2 | 37% |
|
| Beta | 0.79 | 0.95 | 46% |
|
| Avg Daily Volume (000s) | 520 | 455 | 59% |
|
| Price Change (52-week) |
186.0% | 52.9% | 97% |
|
| Growth | TYRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (66.8%) | (9.9%) | 4% |
|
| EPS (5yr) | 19.8% | 16.0% | 67 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 14 | |
| Current EPS | ($0.645) | ($2.567) | ($2.856) | |
| Month Ago EPS | ($0.644) | ($2.551) | ($2.819) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.574) | ($2.318) | ($2.566) | |
| Year/Year Chg | 1.3% | 27.6% | 42.2% | |
| Financials | TYRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($131) | ($43) | 9% |
|
| EPS (TTM) | ($2.178) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($102) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($16) | $5 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $5 | 25% |
|
| Enterprise Value (Q1) (Mil) | $1,775 | $180 | 48% |
|
| Valuation | TYRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.89 | 2.56 | 78% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | TYRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (34.7%) | (49.8%) | 15% |
|
| ROE | (36.9%) | (55.5%) | 18% |
|
| Liabilities to Assets | 5.9% | 30.3% | 3% |
|
| F-Score | 1 | 3 | 1% |
|
Tyra Biosciences, Inc. did not pass any screens on 7/31/2026.
